Velicept feels urge to address OA bladder market with solabegron
By Marie Powers
Thursday, December 17, 2015
Overactive bladder and IBS aren't the sexiest indications in the drug development universe, but tens of millions of patients remain untreated or undertreated.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.